Can-Fite BioPharma Ltd. (CANF)
Stock Price:
$2.26 USD
0.07 (3.24%)
Updated Aug 14, 2020 1:05 PM EDT - Market open
Key Info
| Market Cap |
34.82M |
| Revenue (ttm) |
596,580 |
| Net Income (ttm) |
-2.81M |
| Shares Out |
15.41M |
| EPS (ttm) |
-3.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 14, 2020 |
| Last Price |
$2.26 |
| Previous Close |
$2.19 |
| Change ($) |
0.07 |
| Change (%) |
3.24% |
| Day's Open |
2.23 |
| Day's Range |
2.19 - 2.30 |
| Day's Volume |
323,707 |
| 52-Week Range |
1.08 - 4.95 |
More Stats
| Market Cap |
34.82M |
| Enterprise Value |
34.02M |
| Earnings Date (est) |
Aug 28, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.41M |
| Float |
7.82M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-3.06 |
| FCF / Share |
-2.36 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
119,521 |
| Short Ratio |
0.21 |
| Short % of Float |
n/a |
| Beta |
1.11 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
58.36 |
| PB Ratio |
38.67 |
| Revenue |
596,580 |
| Operating Income |
-3.52M |
| Net Income |
-2.81M |
| Free Cash Flow |
-3.17M |
| Net Cash |
799,159 |
| Net Cash / Share |
0.05 |
| Gross Margin |
100.00% |
| Operating Margin |
-590.70% |
| Profit Margin |
-471.80% |
| FCF Margin |
-531.64% |
| ROA |
-105.04% |
| ROE |
-291.00% |
| ROIC |
n/a |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$6.00*
(165.37% upside)
Low
5.00
Current: $2.26
High
7.00
Target: 6.00
*Average 12-month USD price target from 2 stock analysts.
Financial Performance
Financial numbers in millions ILS.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 2.03 | 3.82 | 0.79 | 0.17 | 0.64 | - | - | - | 1.79 | 2.64 |
| Revenue Growth | -46.81% | 384.16% | 378.18% | -74.34% | - | - | - | - | -32.49% | - |
| Gross Profit | 2.03 | 3.82 | 0.79 | 0.17 | 0.64 | - | - | - | 1.79 | 2.64 |
| Operating Income | -12.00 | -5.41 | -7.19 | -8.68 | -25.04 | -27.77 | -31.31 | -22.43 | -6.62 | -13.35 |
| Net Income | -9.59 | -6.57 | -6.43 | -8.39 | -19.77 | -24.52 | -30.81 | -21.93 | -28.37 | - |
| Shares Outstanding | 2.69 | 2.22 | 1.85 | 1.84 | 1.42 | 1.05 | 1.05 | - | - | - |
| Earnings Per Share | -0.22 | -0.34 | -0.38 | -9.00 | -24.30 | -40.50 | -63.60 | -62.40 | -81.60 | -45.00 |
| Operating Cash Flow | -10.80 | -4.16 | -8.97 | -8.71 | -18.16 | -28.53 | -30.06 | -16.24 | -20.92 | -12.97 |
| Capital Expenditures | - | -0.03 | -0.01 | -0.01 | -0.17 | -0.04 | -0.04 | 0.08 | 0.08 | -0.11 |
| Free Cash Flow | -10.80 | -4.19 | -8.98 | -8.72 | -18.33 | -28.57 | -30.09 | -16.17 | -20.84 | -13.07 |
| Cash & Equivalents | 2.76 | 3.89 | 3.51 | 31.20 | 66.03 | 36.09 | 20.77 | 4.28 | 14.62 | 0.00 |
| Total Debt | 0.04 | - | - | - | - | - | - | - | - | - |
| Net Cash / Debt | 2.72 | 3.89 | 3.51 | 31.20 | 66.03 | 36.09 | 20.77 | 4.28 | 14.62 | 0.00 |
| Assets | 8.18 | 7.95 | 7.61 | 39.11 | 68.71 | 39.67 | 23.11 | 6.11 | 18.66 | - |
| Liabilities | 7.30 | 4.94 | 2.60 | 24.21 | 27.94 | 12.97 | 7.58 | 8.75 | 6.13 | - |
| Book Value | 0.88 | 3.02 | 5.01 | 14.87 | 40.27 | 25.24 | 13.23 | -2.65 | 10.31 | - |
Numbers in millions ILS, except per-share numbers.
Company Details
| Full Name |
Can-Fite BioPharma Ltd. |
| Country |
Israel |
| Employees |
8 |
| CEO |
Pnina Fishman |
Stock Information
| Ticker Symbol |
CANF |
| Stock Exchange |
NYSE American |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NYSEAMERICAN: CANF |
Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. Can-Fite BioPharma Ltd. has collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.